Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
ORIC Stock Chart & Stats
$10.15
-$0.67(-7.21%)
At close: 4:00 PM EST
$10.15
-$0.67(-7.21%)
Day’s Range― - ―
52-Week Range$4.52 - $14.93
Previous CloseN/A
Volume181.02K
Average Volume (3M)2.24M
Market Cap
$1.02B
Enterprise Value$984.52M
Total Cash (Recent Filing)$281.49M
Total Debt (Recent Filing)$11.55M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
May 11, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding100,358,240
10 Day Avg. Volume3,547,337
30 Day Avg. Volume2,243,665
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)1.87
Price to Sales (P/S)0.00
P/FCF Ratio-6.30
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.08K
Enterprise Value/Ebitda-7.37
Forecast
1Y Price Target
$20.30Price Target Upside100.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical CatalystsMultiple planned clinical readouts, including dose‑optimization results for ORIC‑944 and updated enozertinib data, could provide pivotal data to support registrational decisions and investor reassessment.
Safety ProfileRinzimetostat demonstrated efficacy broadly comparable to a competing therapy while showing a notably more favorable safety profile in combination treatment, increasing the likelihood of clinician adoption in prostate cancer.
Strategic Development FlexibilityManagement's initial selection of darolutamide to minimize drug‑drug interaction risks, combined with the option to evaluate apalutamide in future trials, preserves flexibility to optimize combination regimens and address safety concerns.
Bears Say
Class Safety ConcernsVoluntary withdrawal of a peer's drug due to secondary hematologic malignancies has raised class‑wide safety concerns and exerted downward pressure on the stock.
Competitive Landscape And Market TimingA crowded EGFR exon20 lung cancer field and the risk of delayed market entry relative to competitors could materially constrain future market penetration even with comparable efficacy.
Trial Data RobustnessSmall patient sample sizes and absence of tumor imaging response data limit confidence in the durability and clinical relevance of reported efficacy signals.
Oric Pharmaceuticals News
ORIC FAQ
What was Oric Pharmaceuticals’s price range in the past 12 months?
Oric Pharmaceuticals lowest stock price was $4.52 and its highest was $14.93 in the past 12 months.
What is Oric Pharmaceuticals’s market cap?
Oric Pharmaceuticals’s market cap is $1.02B.
When is Oric Pharmaceuticals’s upcoming earnings report date?
Oric Pharmaceuticals’s upcoming earnings report date is May 11, 2026 which is in 29 days.
How were Oric Pharmaceuticals’s earnings last quarter?
Oric Pharmaceuticals released its earnings results on Feb 23, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.34 by $0.04.
Is Oric Pharmaceuticals overvalued?
According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued.
Does Oric Pharmaceuticals pay dividends?
Oric Pharmaceuticals does not currently pay dividends.
What is Oric Pharmaceuticals’s EPS estimate?
Oric Pharmaceuticals’s EPS estimate is -0.32.
How many shares outstanding does Oric Pharmaceuticals have?
Oric Pharmaceuticals has 100,358,240 shares outstanding.
What happened to Oric Pharmaceuticals’s price movement after its last earnings report?
Oric Pharmaceuticals reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.34. Following the earnings report the stock price went up 14.603%.
Which hedge fund is a major shareholder of Oric Pharmaceuticals?
Currently, no hedge funds are holding shares in ORIC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oric Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.30 (100.00% Upside)
$20.30 (100.00% Upside)
Blogger Sentiment
Neutral
ORIC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 18.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 8.0%
Last 30 Days ▲ 8.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
135.49%
12-Months-Change
Fundamentals
Return on Equity
-38.79%
Trailing 12-Months
Asset Growth
48.52%
Trailing 12-Months
Company Description
Oric Pharmaceuticals
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
ORIC Stock 12 Month Forecast
Average Price Target
$20.30
▲(100.00% Upside)
Technical Analysis
Spyre Therapeutics
―
Trevi Therapeutics
―
Praxis Precision Medicines
―
Pharming Group
―
Prime Medicine, Inc.
―
Ownership Overview
Currently, No data available
---